Mutations involving receptor tyrosine kinases (such as FLT3), RAS pathway, CEBPA, and IDH are more common in AML, whereas mutations in the spliceosome complex and epigenetic regulators are more frequent in MDS. Here, IDH1 is linked to acute myeloid leukemia.